Overview

NCI Definition: A rare B-cell non-Hodgkin lymphoma that is characterized by the abnormal rearrangement of two genes, MYC gene and either BCL2 or BCL6 genes. Patients with this type of lymphoma usually respond poorly to standard treatments and have a poor prognosis. [1]

Significant Genes in Double-Hit Lymphoma

ABL1 +

AFF1 +

ALK +

ASXL1 +

BCL2 +

BCL6 +

BCR +

CBFB +

CD274 +

DEK +

ELL +

FGFR3 +

FLT3 +

HRAS +

IGH +

IRF4 +

JAK2 +

KIT +

KMT2A +

KRAS +

MAF +

MAFB +

MECOM +

MLLT1 +

MLLT10 +

MLLT3 +

MLLT4 +

MYC +

MYCN +

MYH11 +

NRAS +

NRIP3 +

NUP214 +

RPN1 +

RUNX1 +

RUNX1T1 +

TP53 +

WHSC1 +

Disease Details

Synonyms
DHL, Double Hit Lymphoma, DH Lymphoma, High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements
Parent(s)
High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.